DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Naloxone in Treating Constipation in Patients Who Are Receiving Opioids for Chronic Pain

Phase 3

Conditions: Constipation, Impaction, and Bowel Obstruction
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-04-05

Last Posted Date: 2018-12-13

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT00020605

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

High-dose ICE With Amifostine

Phase 2

Completed

Conditions: Bladder Cancer
Brain and Central Nervous System Tumors
Carcinoma of Unknown Primary
Extragonadal Germ Cell Tumor
Head and Neck Cancer
Kidney Cancer
Lung Cancer
Ovarian Cancer
Sarcoma
Testicular Germ Cell Tumor

Interventions: Biological: filgrastim
Drug: Amifostine
Drug: Carboplatin
Drug: Etoposide
Drug: Ifosfamide
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2004-03-31

Last Posted Date: 2017-01-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 24

Registration Number: NCT00003657

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Trastuzumab

First Posted Date: 2004-03-15

Last Posted Date: 2017-04-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 14

Registration Number: NCT00004163

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Yale-New Haven Hospital, New Haven, Connecticut, United States

and more 7 locations

Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: docetaxel

First Posted Date: 2004-03-04

Last Posted Date: 2017-07-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 19

Registration Number: NCT00005096

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Valdecoxib in Treating Chronic Pain in Cancer Patients

Not Applicable

Completed

Conditions: Pain
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-02-27

Last Posted Date: 2013-07-18

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT00021996

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Inhaled Morphine Compared With Morphine By Mouth in Treating Cancer Patients With Breakthrough Pain

Phase 2

Completed

Conditions: Pain
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-02-27

Last Posted Date: 2013-07-18

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT00020618

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Biological: rV-DF3/MUC1

First Posted Date: 2003-12-10

Last Posted Date: 2017-02-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00003761

Locations: 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors
Gastrointestinal Stromal Tumor
Sarcoma

First Posted Date: 2003-10-07

Last Posted Date: 2010-12-28

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT00069940

Locations: 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Device: Hyperthermia
Radiation: XRT

First Posted Date: 2003-07-11

Last Posted Date: 2017-04-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 38

Registration Number: NCT00003045

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Rosiglitazone in Treating Patients With Liposarcoma

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: rosiglitazone maleate

First Posted Date: 2003-05-09

Last Posted Date: 2023-06-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 32

Registration Number: NCT00004180

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy